Skip to main content
Erschienen in: Clinical & Experimental Metastasis 7/2009

01.10.2009 | Research Paper

Establishment and characterization of a new highly metastatic human osteosarcoma cell line

verfasst von: Yuxi Su, Xiaoji Luo, Bai-Cheng He, Yi Wang, Liang Chen, Guo-Wei Zuo, Bo Liu, Yang Bi, Jiayi Huang, Gao-Hui Zhu, Yun He, Quan Kang, Jinyong Luo, Jikun Shen, Jin Chen, Xianqing Jin, Rex C. Haydon, Tong-Chuan He, Hue H. Luu

Erschienen in: Clinical & Experimental Metastasis | Ausgabe 7/2009

Einloggen, um Zugang zu erhalten

Abstract

Osteosarcoma is the most common primary malignancy of bone in children and young adults. There is a paucity of tumorigenic and highly metastatic human osteosarcoma cell lines that have not been further transformed by exogenous means. Here we establish and characterize a highly metastatic human osteosarcoma cell line that is derived from a poorly metastatic MG63 line through serial passage in nude mice via intratibial injections. The occasional pulmonary metastases developed from MG63 were harvested and repassaged in mice until a highly metastatic subline (MG63.2) was established. The parental MG63 and highly metastatic MG63.2 cells were further characterized in vitro and in vivo. MG63.2 cells demonstrated increased cell migration and invasion compared to the parental MG63 cells. Conversely, cell adhesion was significantly greater in MG63 cells when compared to the MG63.2 cells. MG63.2 cells grew at a slightly slower rate than that of the parental cells. When injected into nude mice, MG63.2 cells had a greater than 200-fold increase in developing pulmonary metastases compared to the parental MG63 cells. MG63.2 cells also formed larger primary tumors when compared to the parental MG63 cells. Further analysis revealed that ezrin expression was up-regulated in the metastatic MG63.2 cells. Interestingly, expressions of MMP-2 and MMP-9 were down-regulated, and expression of TIMP-2 was up-regulated in the MG63.2 cells. Taken together, we have established and characterized a highly metastatic human osteosarcoma cell line that should serve as a valuable tool for future investigations on the pathogenesis, metastasis, and potential treatments of human osteosarcoma.
Literatur
1.
Zurück zum Zitat Murphey MD, Robbin MR, McRae GA et al (1997) The many faces of osteosarcoma. Radiographics 17(5):1205–1231PubMed Murphey MD, Robbin MR, McRae GA et al (1997) The many faces of osteosarcoma. Radiographics 17(5):1205–1231PubMed
3.
Zurück zum Zitat Link MP, Goorin AM, Miser AW et al (1986) The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 314(25):1600–1606PubMed Link MP, Goorin AM, Miser AW et al (1986) The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 314(25):1600–1606PubMed
4.
Zurück zum Zitat Ward WG, Mikaelian K, Dorey F et al (1994) Pulmonary metastases of stage IIB extremity osteosarcoma and subsequent pulmonary metastases. J Clin Oncol 12(9):1849–1858PubMed Ward WG, Mikaelian K, Dorey F et al (1994) Pulmonary metastases of stage IIB extremity osteosarcoma and subsequent pulmonary metastases. J Clin Oncol 12(9):1849–1858PubMed
9.
Zurück zum Zitat Kager L, Zoubek A, Potschger U et al (2003) Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol 21(10):2011–2018. doi:10.1200/JCO.2003.08.132 CrossRefPubMed Kager L, Zoubek A, Potschger U et al (2003) Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol 21(10):2011–2018. doi:10.​1200/​JCO.​2003.​08.​132 CrossRefPubMed
12.
Zurück zum Zitat Solheim OP, Saeter G, Elomaa I et al (1992) The treatment of osteosarcoma: present trends. The Scandinavian Sarcoma Group experience. Ann Oncol 3(Suppl 2):S7–S11PubMed Solheim OP, Saeter G, Elomaa I et al (1992) The treatment of osteosarcoma: present trends. The Scandinavian Sarcoma Group experience. Ann Oncol 3(Suppl 2):S7–S11PubMed
14.
Zurück zum Zitat Gorlick R, Anderson P, Andrulis I et al (2003) Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary. Clin Cancer Res 9(15):5442–5453PubMed Gorlick R, Anderson P, Andrulis I et al (2003) Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary. Clin Cancer Res 9(15):5442–5453PubMed
17.
Zurück zum Zitat Feugeas O, Guriec N, Babin-Boilletot A et al (1996) Loss of heterozygosity of the RB gene is a poor prognostic factor in patients with osteosarcoma. J Clin Oncol 14(2):467–472PubMed Feugeas O, Guriec N, Babin-Boilletot A et al (1996) Loss of heterozygosity of the RB gene is a poor prognostic factor in patients with osteosarcoma. J Clin Oncol 14(2):467–472PubMed
18.
Zurück zum Zitat Yokoyama R, Schneider-Stock R, Radig K et al (1998) Clinicopathologic implications of MDM2, p53 and K-ras gene alterations in osteosarcomas: MDM2 amplification and p53 mutations found in progressive tumors. Pathology. Res Pract 194(9):615–621 Yokoyama R, Schneider-Stock R, Radig K et al (1998) Clinicopathologic implications of MDM2, p53 and K-ras gene alterations in osteosarcomas: MDM2 amplification and p53 mutations found in progressive tumors. Pathology. Res Pract 194(9):615–621
20.
Zurück zum Zitat Misdorp W, Hart AA (1979) Some prognostic and epidemiologic factors in canine osteosarcoma. J Natl Cancer Inst 62(3):537–545PubMed Misdorp W, Hart AA (1979) Some prognostic and epidemiologic factors in canine osteosarcoma. J Natl Cancer Inst 62(3):537–545PubMed
21.
22.
Zurück zum Zitat Haines DM, Bruland OS, Matte G et al (1992) Immunoscintigraphic detection of primary and metastatic spontaneous canine osteosarcoma with F(ab’)2 fragments of osteosarcoma-associated monoclonal antibody TP-1. Anticancer Res 12(6B):2151–2157PubMed Haines DM, Bruland OS, Matte G et al (1992) Immunoscintigraphic detection of primary and metastatic spontaneous canine osteosarcoma with F(ab’)2 fragments of osteosarcoma-associated monoclonal antibody TP-1. Anticancer Res 12(6B):2151–2157PubMed
23.
24.
Zurück zum Zitat Berlin O, Samid D, Donthineni-Rao R et al (1993) Development of a novel spontaneous metastasis model of human osteosarcoma transplanted orthotopically into bone of athymic mice. Cancer Res 53(20):4890–4895PubMed Berlin O, Samid D, Donthineni-Rao R et al (1993) Development of a novel spontaneous metastasis model of human osteosarcoma transplanted orthotopically into bone of athymic mice. Cancer Res 53(20):4890–4895PubMed
25.
Zurück zum Zitat McGary EC, Heimberger A, Mills L et al (2003) A fully human antimelanoma cellular adhesion molecule/MUC18 antibody inhibits spontaneous pulmonary metastasis of osteosarcoma cells in vivo. Clin Cancer Res 9(17):6560–6566PubMed McGary EC, Heimberger A, Mills L et al (2003) A fully human antimelanoma cellular adhesion molecule/MUC18 antibody inhibits spontaneous pulmonary metastasis of osteosarcoma cells in vivo. Clin Cancer Res 9(17):6560–6566PubMed
27.
Zurück zum Zitat Hensler PJ, Annab LA, Barrett JC et al (1994) A gene involved in control of human cellular senescence on human chromosome 1q. Mol Cell Biol 14(4):2291–2297PubMed Hensler PJ, Annab LA, Barrett JC et al (1994) A gene involved in control of human cellular senescence on human chromosome 1q. Mol Cell Biol 14(4):2291–2297PubMed
28.
Zurück zum Zitat Heremans H, Billiau A, Cassiman JJ et al (1978) In vitro cultivation of human tumor tissues. II. Morphological and virological characterization of three cell lines. Oncology 35(6):246–252CrossRefPubMed Heremans H, Billiau A, Cassiman JJ et al (1978) In vitro cultivation of human tumor tissues. II. Morphological and virological characterization of three cell lines. Oncology 35(6):246–252CrossRefPubMed
29.
Zurück zum Zitat Haydon RC, Zhou L, Feng T et al (2002) Nuclear receptor agonists as potential differentiation therapy agents for human osteosarcoma. Clin Cancer Res 8(5):1288–1294PubMed Haydon RC, Zhou L, Feng T et al (2002) Nuclear receptor agonists as potential differentiation therapy agents for human osteosarcoma. Clin Cancer Res 8(5):1288–1294PubMed
31.
Zurück zum Zitat Oliver MH, Harrison NK, Bishop JE et al (1989) A rapid and convenient assay for counting cells cultured in microwell plates: application for assessment of growth factors. J Cell Sci 92(Pt 3):513–518PubMed Oliver MH, Harrison NK, Bishop JE et al (1989) A rapid and convenient assay for counting cells cultured in microwell plates: application for assessment of growth factors. J Cell Sci 92(Pt 3):513–518PubMed
32.
Zurück zum Zitat Radjabi AR, Sawada K, Jagadeeswaran S et al (2008) Thrombin induces tumor invasion through the induction and association of matrix metalloproteinase-9 and beta1-integrin on the cell surface. J Biol Chem 283(5):2822–2834. doi:10.1074/jbc.M704855200 CrossRefPubMed Radjabi AR, Sawada K, Jagadeeswaran S et al (2008) Thrombin induces tumor invasion through the induction and association of matrix metalloproteinase-9 and beta1-integrin on the cell surface. J Biol Chem 283(5):2822–2834. doi:10.​1074/​jbc.​M704855200 CrossRefPubMed
36.
Zurück zum Zitat Skubitz AP (2002) Adhesion molecules. Cancer Treat Res 107:305–329PubMed Skubitz AP (2002) Adhesion molecules. Cancer Treat Res 107:305–329PubMed
38.
39.
Zurück zum Zitat Ferrari C, Benassi S, Ponticelli F et al (2004) Role of MMP-9 and its tissue inhibitor TIMP-1 in human osteosarcoma: findings in 42 patients followed for 1–16 years. Acta Orthop Scand 75(4):487–491PubMedCrossRef Ferrari C, Benassi S, Ponticelli F et al (2004) Role of MMP-9 and its tissue inhibitor TIMP-1 in human osteosarcoma: findings in 42 patients followed for 1–16 years. Acta Orthop Scand 75(4):487–491PubMedCrossRef
40.
Zurück zum Zitat Cho HJ, Lee TS, Park JB et al (2007) Disulfiram suppresses invasive ability of osteosarcoma cells via the inhibition of MMP-2 and MMP-9 expression. J Biochem Mol Biol 40(6):1069–1076PubMed Cho HJ, Lee TS, Park JB et al (2007) Disulfiram suppresses invasive ability of osteosarcoma cells via the inhibition of MMP-2 and MMP-9 expression. J Biochem Mol Biol 40(6):1069–1076PubMed
41.
Zurück zum Zitat Khanna C, Khan J, Nguyen P et al (2001) Metastasis-associated differences in gene expression in a murine model of osteosarcoma. Cancer Res 61(9):3750–3759PubMed Khanna C, Khan J, Nguyen P et al (2001) Metastasis-associated differences in gene expression in a murine model of osteosarcoma. Cancer Res 61(9):3750–3759PubMed
45.
47.
Zurück zum Zitat Li W, Zeng JC, Pei FX et al (2007) Establishment of orthotopic model of MG-63 osteosarcoma. Sichuan Da Xue Xue BaoYi Xue Ban 38(2):321–323 Li W, Zeng JC, Pei FX et al (2007) Establishment of orthotopic model of MG-63 osteosarcoma. Sichuan Da Xue Xue BaoYi Xue Ban 38(2):321–323
Metadaten
Titel
Establishment and characterization of a new highly metastatic human osteosarcoma cell line
verfasst von
Yuxi Su
Xiaoji Luo
Bai-Cheng He
Yi Wang
Liang Chen
Guo-Wei Zuo
Bo Liu
Yang Bi
Jiayi Huang
Gao-Hui Zhu
Yun He
Quan Kang
Jinyong Luo
Jikun Shen
Jin Chen
Xianqing Jin
Rex C. Haydon
Tong-Chuan He
Hue H. Luu
Publikationsdatum
01.10.2009
Verlag
Springer Netherlands
Erschienen in
Clinical & Experimental Metastasis / Ausgabe 7/2009
Print ISSN: 0262-0898
Elektronische ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-009-9259-6

Weitere Artikel der Ausgabe 7/2009

Clinical & Experimental Metastasis 7/2009 Zur Ausgabe

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Bessere Prognose mit links- statt rechtsseitigem Kolon-Ca.

06.05.2024 Kolonkarzinom Nachrichten

Menschen mit linksseitigem Kolonkarzinom leben im Mittel zweieinhalb Jahre länger als solche mit rechtsseitigem Tumor. Auch aktuell ist das Sterberisiko bei linksseitigen Tumoren US-Daten zufolge etwa um 11% geringer als bei rechtsseitigen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.